Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo by Jeffery M. Cowden et al.
ORIGINAL RESEARCH PAPER
Antagonism of the histamine H4 receptor reduces LPS-induced
TNF production in vivo
Jeffery M. Cowden • Fuqu Yu • Mamatha Challapalli • Jing-Feng Huang •
Sunhwa Kim • Wai-Ping Fung-Leung • Jing Ying Ma • Jason P. Riley •
Mai Zhang • Paul J. Dunford • Robin L. Thurmond
Received: 26 September 2012 / Revised: 16 November 2012 / Accepted: 6 March 2013 / Published online: 27 March 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Objective Antagonism of the histamine H4 receptor
(H4R) has been shown to be anti-inflammatory in a number
of preclinical disease models, however the exact mecha-
nisms behind this are still being uncovered. In vitro, the
receptor interacts with TLR and impacts inflammatory
mediator production from a number of different cell types.
Here it is shown that this interaction also occurs in vivo.
Materials and methods Wild-type and H4R deficient
BALB/c mice received an i.p. injection of LPS in PBS in
conjunction with p.o. JNJ 7777120 or JNJ 28307474 (H4R
antagonists). Two hours later blood was collected and TNF
was measured.
Results Two different H4R antagonists inhibited LPS-
induced TNF production in mice and this production was
also reduced in H4R-deficient mice. The TNF mRNA
analysis showed that the major source of the cytokine was
the liver and not blood, and that the H4R antagonist only
reduced the expression levels in the liver. Depletion or
inactivation of macrophages reduced the TNF levels and
eliminated the H4R sensitivity. Treatment with an H4R
antagonist also reduced LPS-induced liver injury and
blocked LPS-enhanced lung inflammation in mice.
Conclusion The data support an interaction between H4R
and TLR activation in vivo that can drive inflammatory
responses.
Keywords Histamine  Macrophages  Kupffer cells 
Toll-like receptors
Abbreviations






The histamine H4 receptor (H4R) has been implicated in a
variety of pathophysiological functions due to effects seen
in preclinical models [1]. Most of the data have involved
effects on inflammatory processes. H4R antagonists
reduced inflammation in mouse models of asthma [2, 3]
and dermatitis [4] and similar effects were observed with
H4R-deficient mice [2, 4]. However, the exact molecular
mechanisms are not clear. The H4R has been shown to
mediate chemotaxis of cells such as eosinophils [5, 6], mast
cells [7, 8] and dendritic cells [9, 10] and this may explain
some of its role in inflammation. In addition, the receptor
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has been shown to modulate inflammatory mediator pro-
duction in vitro from dendritic cells, mast cells, T cells and
monocytes [2, 11–13]. In most cases, these findings have
been in the context of TLR stimulation and it is intriguing
to speculate that there may be an interaction between
inflammatory signals that activate TLR pathways and those
that activate the H4R. Indeed, in mouse mast cells it has
been shown that the H4R can potentiate LPS-induced IL-6
production and this interaction occurs at the level of kinase
activation [11].
Here the role of the H4R in TLR-driven inflammation is
explored in vivo. The LPS-induced TNF production in vivo
is inhibited in H4R-deficient mice or by treatment with H4R
antagonists. The interaction between the H4R and TLR




Wild-type BALB/c mice were obtained from Charles River
Laboratories (Wilmington, MA). H4R deficient mice were
generated by Lexicon Genetics (Woodlands Park, TX) as
previously described [7]. Mice were housed in community
cages on a 12-h light cycle and fed mouse chow and water
ad libitum. All procedures were performed according to the
internationally accepted guidelines for the care and use of
laboratory animals in research and were approved by the
local Institutional Animal Care and Use Committee. The
JNJ 7777120 and JNJ 28307474 (H4R antagonists) were
synthesized as previously described [4, 14]. In all cases
H4R antagonists were delivered p.o. in 20 % hydroxy-
propyl-b-cyclodextran. Lipopolysaccharide (E.coli 0111:B4),
methylpalmitate (MP; stock 200 mg/ml in 5 % glucose
solution containing 0.2 % Tween-20) and galactosamine
(GaIN) were purchased from Sigma-Aldrich, LLC, (St.
Louis, MO). Clodronate liposomes (CL) were purchased
from ClodronateLiposomes.org (Amsterdam, Netherlands)
in a stock solution of around 5 mg/ml in PBS. The
stock was further diluted in PBS to 1 mg/ml just before
administration and tail vein injection at *200 ll/mouse.
The TNF ELISA was obtained from R&D Systems, Inc.
(Minneapolis, MN). Low endotoxin RPMI media was from
Sigma-Aldrich Co. LLC. (St. Louis, MO).
In vivo LPS model
Female wild-type or H4R-deficient mice were administered
vehicle, JNJ 7777120 or JNJ 28307474 p.o. Thirty minutes
later, the mice received an i.p. injection of 20 lg of LPS in
PBS. The dose of LPS was selected based on pilot
experiments and is consistent with previous reports [15].
Two hours later blood was collected and serum cytokines
were measured via ELISA. To assess the activation of
NFjB and AP-1, nuclear and cytoplasmic fractions of
whole liver tissue sections were prepared using Nuclear
Extraction Kit (Active Motif, Carlsbad, CA) with the
manufacturer’s protocol. Five lg of proteins from each
fraction of individual samples were analyzed for the
phosphorylation and/or nuclear translocation of NFjB and
AP-1 transcription factors utilizing TransAM NFjB Fam-
ily Kit (Active Motif, Carlsbad, CA) and TransAM AP-1
Family Kit (Active Motif, Carlsbad, CA) according to the
manufacturer’s protocol.
Kupffer cell depletion
For Kupffer cell depletion, the mice were treated by tail
vein injection with either vehicle, 2 g/kg MP or 10 mg/kg
CL (the vehicle for CL was empty liposomes in PBS).
Forty-four hours after treatment with MP or CL 20 lg of
LPS in PBS was administered by i.p. Two hours post LPS
injection, animals were euthanized and blood collected via
cardiac puncture. Serum TNF levels were quantitated by
ELISA. Livers were collected in RNAlater reagent
(Ambion, Inc., Austin, TX) and total RNA was extracted
using RNeasy Plus Mini Kit (QIAGEN, Inc., Valencia,
CA). In addition, blood RNA was extracted using QIAamp
RNA Blood Mini Kit (QIAGEN, Inc. Valencia, CA). The
RNA was reverse-transcribed to cDNA using the Gene-
Amp Gold RNA PCR Core Kit (Applied Biosystems,
Carlsbad, CA). The TNF message levels were detected using
commercially available TaqMan primer/probe sets (Applied
Biosystems, Carlsbad, CA) with 7500 Real Time PCR
System (Applied Biosystems, Carlsbad, CA). The data is
presented as the fold-induction compared to naı¨ve animals.
To assess macrophage depletion, liver samples were
fixed in 10 % formalin for 24 h, processed, paraffin
embedded, sectioned at 5 lm thickness and mounted on the
slides. The slides were deparaffinized and hydrated in PBS
followed by blocking the endogenous peroxide with 3 %
hydrogen peroxide. Incubation with a solution of 3 %
trypsin was used to enhance the binding of the primary
antibody. Avidin and biotin blocks (Vector laboratories,
Burlingame, CA) were used to avoid nonspecific labeling
with primary antibody. To avoid nonspecific reaction with
the secondary antibody, slides were pretreated with 10 %
normal goat serum before incubation with primary anti-
body. Rat anti-mouse F4/80 at a concentration of 1:50
(AbD Serotec, Raleigh, NC) as primary antibody and goat
anti-rat biotinlated IgG as secondary antibody (Cat#AP183b,
Chemicon International, Inc., Temecula, CA) at 1:2,000
concentration were used. Normal rat IgG at 1:50 con-
centration (Cat# CBL606, Chemicon International, Inc.,
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Temecula, CA) was used as a negative control. The
immunoreactivity was visualized by ABC reagent (Vector
Laboratories, Burlingame, CA) and diaminobenzidine
(DAKO, Carpinteria, CA) followed by counterstaining
with Mayer’s hematoxylin. A Nikon E800 light microscope
equipped with a Q Image camera was used to capture
images. Images were measured by Image Pro Plus software
7.0 (MediaCybernetics, Inc., Bethesda, MD). Positively
stained, centro-lobularly located macrophages (Kupffer
cells) were automatically counted in the randomly chosen
five hot fields under the 9100 magnification objective lens
using the cell-count feature of Image Pro Plus 7.0 software.
The mean value of the cell counts in five fields was cal-
culated, defined as cell count per field.
In vitro and ex vivo LPS stimulation of whole blood
For in vitro stimulation, blood from wild-type and H4R-
deficient mice was diluted 1:1.8 with low endotoxin RPMI
media containing vehicle (0.4 % DMSO) or 50 lM JNJ
7777120 and incubated for 1 h at 37 C. After incubation,
10 ng/ml LPS was added and the samples were incubated
for 4 h at 37 C. Cells were centrifuged, supernatants were
harvested and TNF levels were measured by ELISA. For
the ex vivo stimulation, wild-type mice were dosed p.o.
with JNJ 7777120 (1, 5 and 20 mg/kg). Mice were sacri-
ficed 15 min later (the Tmax for the plasma levels of JNJ
7777120) and blood collected. Blood was diluted 1:2 with
low endotoxin RPMI media containing 10 ng/ml LPS and
the samples were incubated for 4 h at 37 C. Cells were
centrifuged, supernatants were harvested and TNF levels
were measured by ELISA.
Immunofluorescence for dual F4/80 and TNF staining
Mice received an i.p. injection of 20 lg of LPS (Sigma-
Aldrich Co. LLC, St. Louis, MO) or vehicle (PBS) and 2 h
later livers, lungs and spleens were harvested and frozen in
tissues cassettes with O.C.T. freezing compound. Immu-
nofluorescence detection was carried out by Seventh Wave
Laboratories LLC (Chesterfield, MO). Rat anti-mouse F4/
80 (monoclonal IgG2b; AbD Serotec) and Dylight 488
mouse anti-rat IgG (green; Thermo Fisher Scientific, Inc.
Rockford, IL) was used for F4/80 detection. Rabbit anti-
human TNF (polyclonal IgG fraction; Sigma-Aldrich Co.
LLC, St. Louis, MO) and Dylight 594 mouse anti-rabbit
IgG (red; Thermo Fisher Scientific, Inc. Rockford, IL) was
used for TNF detection. The 40, 6-diamidino-2-phenylin-
dole was used to provide a nuclear counterstain in all the
sections. The frozen blocks were sectioned (approximately
6 micrometer thickness) to produce one slide per tissue per
mouse, and the sections were immunoreacted to detect
TNF and F4/80 Immunofluorescence. A cocktail of rat
IgG2b and normal rabbit IgG fraction adjusted to the
equivalent protein concentrations as the primary antibodies
was substituted for the primary antibody cocktail for the
negative control sections.
H4R expression in Kupffer cells
Freshly isolated female mouse and human Kupffer cells
were purchased from Celsis In Vitro Technologies (Balti-
more, MD). Total RNA was extracted using RNeasy Plus
Mini Kit from QIAGEN, Inc. (Valencia, CA). The H4R
message levels were detected using commercially available
TaqMan primer/probe sets (Applied Biosystems, Carlsbad,
CA) with 7500 Real Time PCR System (Applied Biosys-
tems, Carlsbad, CA).
Liver injury model
Female mice were treated with 10 mg/kg LPS ? 1 g/kg
GaIN in PBS through tail vein injection. One hour before
LPS ? GaIN treatment, the mice were pretreated with
vehicle or 20 mg/kg JNJ 28307474 p.o. Six hours after
LPS ? GaIN injection, serum was harvested for alanine
transaminase (ALT) measurement using ACE Alera system
(Alfa Wassermann, West Caldwell, NJ).
Mouse asthma model
A mouse asthma model was run as previously described [2]
with the following modifications. Endotoxin was removed
from the OVA by phase separation using Triton X-114 as
previously described [16]. Thirty minutes prior to OVA
aerosol challenge on day 21 through day 24, animals under
light anesthesia were given a 50 ll intranasal dose of PBS
or PBS ? 1 ng LPS. The JNJ 7777120 was given at
20 mg/kg p.o. 30 min prior to LPS.
Results
Previous studies have suggested an interaction between the
H4R and TLR in vitro [2, 11–13, 17–19]. Based on this, the
effects of the H4R on LPS-induced cytokine production
in vivo was assessed. In mice, TNF production can be
detected in serum 2 h after i.p. injection of LPS. When
mice were pretreated with the selective H4R antagonist JNJ
7777120 30 min before LPS administration, the levels of
TNF were dramatically reduced (Fig. 1a). A second
structurally distinct antagonist, JNJ 28307474, was also
found to inhibit LPS-induced TNF production in a dose
dependent fashion, confirming that this effect was due to
antagonism of the H4R, (Fig. 1b). The difference in dose
response between JNJ 7777120 and JNJ 28307474 reflects
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the weaker affinity of the latter for the mouse H4R [4]. In
addition to the pharmacological evidence that this is an
H4R dependent effect, LPS-induced TNF levels were dra-
matically reduced in H4R-deficient mice compared to wild-
type mice and, furthermore, JNJ 7777120 at 50 mg/kg had
no additional effect in H4R-deficient mice (Fig. 1c). The
levels of TNF produced show little variability within each
group, however these levels do vary across experiments run
at different times. The consistent findings in H4R-deficient
mice and with two structurally distinct antagonists confirm
that the suppressive effect on LPS-induced TNF production
in vivo is due to antagonism of the H4R.
Fig. 2 H4R antagonists do not inhibit TNF production in vitro or
ex vivo. a Mouse whole blood was stimulated in vitro with LPS
(10 ng/ml) for 4 h and then TNF levels were measured. Blood from
BALB/c wild-type mice (WT) and H4R-deficient mice (KO) was
used. In addition, 50 lM of JNJ 7777120 was added to blood from
wild-type mice (WT JNJ) 1 h prior in stimulation with LPS. The
analysis was carried out in triplicate and the average along with SEM
is plotted. There was no significant difference in the TNF levels
between any of the groups. b Wild-type mice (9–10 mice per group)
were dosed p.o. with vehicle or JNJ 7777120 at the doses given.
Fifteen minutes later blood was collected and stimulated with LPS
(10 ng/ml) for 4 h before TNF levels were measured. There was no
significant difference in TNF levels between any of the groups
Fig. 1 H4R antagonists inhibit TNF production in vivo. Wild-type
mice (n = 5–6 mice per group) were treated orally with either
vehicle, JNJ 7777120 (a) or JNJ 28307474 (b) 30 min prior to i.p.
administration of LPS (20 lg). Two hours later the levels of TNF in
the serum were analyzed by ELISA. (C) LPS (20 lg) induced serum
TNF levels in wild-type (WT) mice but not in H4R-deficient mice
(KO). In addition, JNJ 7777120 reduced the TNF levels in wild-type
mice, but not in the H4R-deficient mice. Six to eight mice were used
per group. For all panels the average along with SEM is plotted.
***p \ 0.001 by one-way ANOVA with post hoc Bonferroni’s test
compared vehicle administration in wild-type animals
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Monocytes and macrophages are the most likely source
of TNF in this model and, therefore, the effects of H4R
inhibition on TNF production in whole blood in vitro were
explored. Blood from mice was pretreated with JNJ
7777120 in vitro before LPS stimulation. The TNF was
produced but no inhibition by JNJ 7777120 was detected
(Fig. 2a). The same result was observed with blood from
H4R-deficient mice compared to wild-type mice (Fig. 2a).
This was also the case for ex vivo stimulation of whole
blood. Animals were administered various doses of JNJ
7777120 and afterwards blood was stimulated with LPS.
Once again, there was no inhibition of TNF production
(Fig. 2b). Therefore, H4R antagonism inhibited LPS-
induced TNF levels in vivo, but not when blood was
stimulated directly. This suggests that monocytes in the
blood were not the source of TNF production by LPS
in vivo.
Tissue resident macrophages are also a potential source
of TNF in vivo. In particular, liver resident macrophages
are known to respond to inflammatory stimuli. To probe
this, methylpalmitate (MP) was used to inactivate tissue
resident macrophages. As shown previously, MP does not
deplete macrophages (Figure S1) and instead inactivates
them [20]. Treatment with MP reduced the LPS-induced
TNF production close to baseline levels. Treatment with
the H4R antagonist had no further effect on the TNF levels
(Fig. 3a). To further explore this finding, clodronate lipo-
somes (CL) were used to deplete liver macrophages.
Immunohistochemistry staining with F4/80 was used to
show that the protocol reduced liver resident macrophage
(Figure S2). As with MP, CL treatment reduced the serum
levels of TNF to a comparable level as with JNJ 7777120
treatment alone, although in both cases the levels were still
slightly higher than the level observed in naı¨ve animals
(Fig. 3b). Treatment with JNJ 7777120 after CL depletion
of macrophages had no effect on TNF production. This
suggests that the source of LPS-induced TNF in vivo may
be liver resident macrophages. To confirm this, TNF
mRNA levels were measured in the liver and in whole
blood after LPS stimulation in vivo. The LPS administra-
tion induced a much higher level of TNF mRNA in the
liver than in blood (Fig. 3c, d). Treatment with JNJ
77777120 suppressed the TNF mRNA level in the liver, but
not in blood (Fig. 3c, d). Furthermore, depletion of tissue
Fig. 3 Depletion of liver macrophages reduces LPS-induced TNF
levels. Female wild-type mice (7–8 mice per group) were treated with
either 20 lg LPS i.p. or LPS i.p. ? 20 mg/kg JNJ 7777120 p.o. In
addition to this, two groups of mice were treated with vehicle, 2 g/kg
MP (a) or 10 mg/kg CL (b–d) 44 h before administration of LPS i.p.
The TNF levels were measured in the serum 2 h after LPS stimulation
(a, b). The serum TNF levels were also measured in naı¨ve mice that
had no treatment. The TNF mRNA levels were quantitated by RT-
PCR in blood (c) and in the liver (d) from animals treated with 20 lg
LPS i.p. ± 20 mg/kg JNJ 7777120 p.o. in the absence or presence of
pretreatment with CL. ns, non-significant; ***p \ 0.001; **p \ 0.01;
*p \ 0.05 by one-way ANOVA with post hoc Bonferroni’s test
compared to LPS alone unless otherwise specified
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macrophages with CL also reduced the TNF mRNA
induction in the liver (Fig. 3d).
To verify that the LPS-induced TNF is derived from
macrophages, immunofluorescence costaining of macro-
phages and intracellular TNF were conducted after in vivo
administration of LPS. In mice not receiving LPS, TNF
was not expressed in the liver (Figure S3). In contrast after
treatment with LPS almost all F4/80 positive cells in the
liver were positive for TNF and all of TNF positive cells
were F4/80 positive (Fig. 4a, b). Treatment with the H4R
antagonist, JNJ 7777120, reduced the percentage of F4/
80?/TNF? cells (Fig. 4b). Therefore, the data suggests that
tissue resident macrophages are the source of LPS-induced
TNF in vivo and that antagonism of the H4R reduces their
activity. This is further supported by the detection of H4R
mRNA in mouse Kupffer cells albeit at very low levels
compared to bone-marrow derived mast cells (data not
shown). Human Kupffer cells can also express low levels
of the H4R, but this was only seen in two of the three
donors tested (data not shown). While liver resident mac-
rophages appeared to express TNF upon LPS stimulation,
most macrophages in the spleen and lung from wild-type
animals did not express TNF with only 11 and 9 %
showing expression, respectively.
Suppression of LPS-induced TNF responses in the liver
by JNJ 7777120 suggests that antagonizing the H4R may
help block inflammatory liver injury. The combination of
galactosamine (GaIN) and LPS administration in mice
leads to increases in ALT indicative of the induction of
liver injury and this effect is driven by TNF production [21,
22]. Treatment with the H4R antagonist JNJ 28307474
blunts the elevation in ALT suggesting that H4R antago-
nism can inhibit inflammation driven liver injury (Fig. 5).
In this case JNJ 28307474 was used instead of JNJ
7777120 since it has a longer half-life in mice and
is more appropriate for the time course of the model
[Table S1 and 8].
The data presented here suggest that the H4R can
mediate LPS responses in the liver and raises the question
whether this is reflected in other tissues. Previous work on
the H4R has shown a role for the receptor in models of
asthma indicating that it can mediate lung inflammation.
Mouse asthma models are known to be sensitive to the
presence of LPS [23, 24]. We exploited this fact to explore
Fig. 4 LPS induces TNF production from F4/80? cells in the liver.
Livers were collected from untreated mice, mice treated with 20 lg
LPS i.p., or mice treated with 20 lg ng/ml LPS i.p. and 20 mg/kg JNJ
7777120. Frozen sections were stained with F4/80 (green) and anti-
TNF (red) and detected by immunofluorescence. A representative
image from a mouse treated with LPS is shown in panel a and
indicates the co-localization of F4/80 and TNF staining. The
percentage of F4/80? cells that were TNF? was quantitated from
multiple animals in each group (b). *p \ 0.05 by t test comparing the
JNJ 7777120 treated and untreated groups (color figure online)
Fig. 5 H4R antagonism inhibits LPS-induced liver injury. Wild-type
mice were pretreated with vehicle (PBS) or JNJ 28307474 before
LPS ? GaIN injection, and serum ALT levels were measured 6 h
later. Statistical significance was determined by one-way ANOVA
with post hoc Bonferroni’s test
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the interaction of LPS and the H4R in a mouse asthma
model. Ovalbumin was first cleaned of any traces of LPS
and then used to challenge mice either in the absence
or presence of 1 ng of LPS. When the ovalbumin was
cleaned of all LPS, the number of eosinophils in the
bronchoalveolar lavage fluid was reduced (compare the
vehicle groups with and without LPS in Fig. 6a). This
effect of low doses of LPS has been described previously
[24]. In the absence of LPS, treatment with JNJ 7777120
had no effect on the remaining inflammation. However,
when LPS was added back, the number of eosinophils
increased and this increase was blocked by the H4R
antagonist (Fig. 6a). A similar effect was seen when the IL-
13 levels from the bronchoalveolar lavage fluid were
measured (Fig. 6b). Therefore, the effect of H4R antago-
nism in this mouse model of asthma was dependent on
TLR pathways being activated and is consistent with an
interaction between TLR and H4R activation.
Discussion
The H4R has been suggested to be involved in immune and
inflammatory responses and antagonists have shown
activity in a number of disease models [1]. However, the
exact mechanisms driving these responses have been
unclear. There appears to be evidence in vitro of an
interaction between inflammation driven by TLR activation
and that driven by H4R activation. It was reported previ-
ously that H4R antagonists can inhibit TLR-driven cytokine
responses in vitro in mouse dendritic cells and mast cells
[2, 11]. In the case of TLR-driven IL-6 production in mast
cells, it was suggested that this was due to an interaction in
activation of downstream kinases like ERK and phospho-
inositide 3-kinase gamma [11]. Therefore, activation of the
H4R may be very important in amplifying TLR signals.
Here we have explored whether a similar interaction occurs
in vivo, and whether it could explain some of the in vivo
anti-inflammatory effects of H4R antagonists.
In this study we have shown that antagonism of the H4R
can inhibit the in vivo production of TNF induced by LPS.
Two different H4R antagonists, JNJ 7777120 and JNJ
28307474, have similar effects and inhibition was also seen
in H4R-deficient mice providing convincing evidence that
the effect seen was due to H4R antagonism. However, in all
cases the level of inhibition was not complete, suggesting
that H4R-independent factors also play a role.
The inhibition seen with the H4R antagonists or in H4R-
deficient animals only occurs when the LPS is administered
in vivo. When LPS is used to induce TNF in whole blood,
in vitro administration of an H4R antagonist does not
inhibit this response. This suggests that cells in the blood
are not the source of TNF in vivo even though they can
produce TNF in vitro. Analysis of TNF RNA levels
showed that LPS increased the TNF message in the liver to
a greater extent than in blood thereby supporting the
hypothesis that tissue resident cells are the source of LPS-
induced TNF. Since H4R antagonism only inhibits TNF
Fig. 6 LPS is required for H4R-dependent sensitivity in a mouse
asthma model. Wild-type mice (n = 5–8 per group) were sensitized
to ovalbumin i.p. on Days 0 and 14 before repeat aerosol exposure to
ovalbumin on Day 21 through 24. The ovalbumin used was either
LPS-free (No LPS) or spiked with 1 ng of LPS. Vehicle (Veh) or JNJ
7777120 (JNJ) was administered p.o. 15 min prior to each challenge.
a The number of eosinophils was calculated from bronchoalveolar
lavage fluid collected 24 h after the last OVA challenge. b IL-13
levels were measured from bronchoalveolar lavage fluid. Statistical
significance was determined by one-way ANOVA with post hoc
Bonferroni’s test; ns indicated not significant
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production by LPS in vivo, it is possible that the receptor is
only active on tissue resident macrophages. The TNF
immunofluorescence can be detected in the liver after LPS
administration and this co-stains with a marker of macro-
phages. H4R expression can also be detected in Kupffer
cells albeit at low levels. As further confirmation of this we
have shown that inhibiting or depleting tissue macrophages
blocked the production of TNF induced by LPS.
The in vivo only inhibitory activity of H4R antagonist on
LPS-induced TNF production is in contrast to other
inhibitors of LPS-induced TNF production like p38 kinase
inhibitors, which have effects in vivo and in vitro [15]. The
difference between resident cells and those derived from
blood has been seen previously with H4R effects on den-
dritic cells. The H4R could mediate TLR driven cytokine
responses in mouse splenic CD11c? cells [2], but not from
mouse monocyte-derived dendritic cells (O’Donnell and
Thurmond, unpublished data). The involvement of H4R in
TNF production in the liver may play a role in liver injury.
The TNF has been shown to be a major mediator of GalN/
LPS induced liver injury [22] and here we show that an
H4R antagonist can inhibit the induction of ALT in this
model.
Currently, the mechanism by which the H4R modulates
LPS-induced TNF production is not known and unraveling
these mechanisms is complicated since the effect only
occurs in vivo. The impact on NFjB and AP-1 activation in
the liver was studied and, although their activation was
increased by LPS, this was not modulated by antagonism of
the H4R (data not shown). However, previously it was
shown that in mouse mast cells there is synergy between
H4R and TLR activation in the production of IL-6 [11]. In
this case, both H4R and TLR activation led to activation of
MAP kinases and phosphoinositide 3-kinase gamma,
however, the combination of both signals did not increase
the levels of kinase activation, but instead led to sustained
activation. This was hypothesized to underlie the increased
IL-6 production in mast cells and may also impact the
TNF production seen in vivo. However, further work is
necessary to completely understand the details of this
interaction.
The impact of the H4R on TLR-induced cytokine
responses both in vivo and in vitro provides a basis for
understanding the anti-inflammatory properties of H4R
antagonists in various animal models. Previously, we have
shown that the H4R can modulate inflammatory responses
in a mouse asthma model and it has been reported that LPS
is necessary for obtaining a robust inflammatory response
in these models [23, 24]. We confirm both of these findings
here and show that LPS was also necessary to evoke an
H4R component of the inflammation. Therefore, the anti-
inflammatory action of an H4R antagonist as previously
shown is dependent on the presence of LPS. It is possible
that TLR activation or other similar signals are required for
the activation of dendritic cells and macrophages and that
these in turn drive T cell-dependent aspects of the model.
Activation of the H4R is needed to amplify TLR responses
on these cells. This interaction may also underlie other
models such as those for colitis. The H4R antagonists block
the inflammation in a rat model of colitis [25]. In this
model chemical damage to the colon exposes submucosal
tissue to bacteria that activate TLR signaling and thereby
drive the inflammatory response. The anti-inflammatory
effects of H4R antagonist in this model may be due to
inhibition of the TLR-driven response. Indeed in the colitis
model, treatment with the H4R antagonists completely
inhibited the increase in tissue TNF levels [25].
In conclusion, antagonism of the H4R can inhibit TLR-
driven inflammatory responses in vivo. This, along with
previously published in vitro data, provides evidence for an
interaction between activation of the H4R and activation of
TLR that drives inflammatory responses. These findings
may have an impact in human diseases since both TLR and
the H4R have been implicated in conditions such as asthma,
autoimmune diseases and atopic dermatitis.
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